Discontinuation of anti-TNF-alpha treatment due to blood test abnormalities and cost-effectiveness of alternate blood monitoring strategies.

Abhishek AbhishekMatthew D StevensonGeorgina NakaferoMatthew J GraingeIan EvansOras AlabasTim CardMaarten W TaalGuruprasad P AithalChristopher P FoxChristian David MallenDanielle A van der WindtRichard D RileyRichard Bruce WarrenHywel C Williams

Published in: The British journal of dermatology (2023)

Anti-TNF-alpha drugs were uncommonly discontinued due to abnormal monitoring blood tests after the first year of treatment. Extending the duration between monitoring blood-tests was cost-effective. Our results produce evidence for specialist society guidance to reduce patient monitoring burden and healthcare costs.

Keyphrases

healthcare
rheumatoid arthritis
palliative care
case report
risk factors
social media
replacement therapy
drug induced
smoking cessation